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peritonitis and mortality in patients with peritoneal dialysis. This study sought to describe international
variation in hypokalemia, potential modifiable hypokalemia risk factors, and the covariate-adjusted rela-
tionship of hypokalemia with peritonitis and mortality.
Methods: Baseline serum potassium was determined in 7421 patients from 7 countries in the Peritoneal
Dialysis Outcomes and Practice Patterns Study (2014–2017). Association of baseline patient and treatment
factors with subsequent serum potassium <4 mEq/l was evaluated by logistic regression, whereas
baseline serum potassium levels (4-month average and fraction of 4 months having hypokalemia) on
clinical outcomes was assessed by Cox regression.
Results: Hypokalemia was more prevalent in Thailand and among black patients in the United States. Char-
acteristics/treatments associated with potassium <4 mEq/l included protein-energy wasting indicators, lower
urine volume, lower blood pressure, higher dialysis dose, greater diuretic use, and not being prescribed a renin-
angiotensin system inhibitor. Persistent hypokalemia (all 4 months vs. 0 months over the 4-month exposure
period) was associated with 80% higher subsequent peritonitis rates (at K<3.5 mEq/l) and 40% higher mortality
(at K <4.0 mEq/l) after extensive case mix/potential confounding adjustments. Furthermore, adjusted peritonitis
rates were higher if having mean serum K over 4 months <3.5 mEq/l versus 4.0–4.4 mEq/l (hazard ratio, 1.15
[95% confidence interval, 0.96–1.37]), largely because of Gram-positive/culture-negative infections.
Conclusions: Persistent hypokalemia is associated with higher mortality and peritonitis even after exten-
sive adjustment for patient factors. Further studies are needed to elucidate mechanisms of these poorer
outcomes and modifiable risk factors for persistent hypokalemia.
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oth high and low serum potassium concentrations
have been associated with higher all-cause and car-
diovascular mortality in patients receiving peritoneal
dialysis (PD),1–5 and even at potassium levels in the
lower end of the normal range.1–3 In The Brazilian PD
Multicenter Study (BRAZPD), serum potassium <4.01
CLINICAL RESEARCH SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PDmEq/l was associated with elevated cardiovascular- and
infection-related mortality and peritonitis risk.2 The
hypothesized mechanism(s) by which low-normal
serum potassium might cause these outcomes are (i)
through increasing the risk of arrhythmia in cardiovas-
cular deaths6 or (ii) by hypokalemia-associated bowel
motility disorders and bacterial intestinal overgrowth
leading to peritonitis caused by enteric organisms.7,8
Alternatively, low serum potassium may be a proxy
for ill health and protein-energy wasting rather than
a cause of increased mortality/peritonitis.
In PD, potassium homeostasis is a balance between
losses (e.g., urinary and dialysate) and dietary intake.
As potassium is predominantly (98%) an intracellular
ion, serum potassium concentrations also are influenced
by transcellular distribution and total body potassium
stores (correlated with muscle mass). This buffering
capacity means that in normal health, elimination of
dietary potassium will not alter serum potassium for 2
or 3 weeks.9,10 In contrast, protein-energy wasting is
commonly observed in patients undergoing dialysis
and is associated with inflammation, muscle wasting,
reduced potassium intake, and total body stores,
increasing the risk of hypokalemia.11–13 Additional
factors that may potentially impact serum potassium
levels in patients with PD include residual kidney
function decline, dialytic removal of potassium (which
may increase as clinicians prescribe more dialysis to
compensate for loss of residual kidney function),
diuretic use, drugs that block the renin-angiotensin
aldosterone system, and the influence of glucose-
containing PD solutions on transcellular shifts of po-
tassium into cells. Cultural dietary differences may also
impact potassium intake.14 Finally, interventions that
alter transcellular distribution or flux (for example,
glycemic control with insulin in diabetics) must also be
considered.
Furthermore, questions remain regarding to what
extent the relationship of hypokalemia with mortality
and peritonitis may differ depending on how hypo-
kalemia is measured/defined and over what period of
time.4 Addressing these questions is important for
informing approaches on how best to minimize poorer
outcomes in relationship to hypokalemia in patinets
with PD. To this end, we have developed the current
investigation, based on prospective, international
Peritoneal Dialysis Outcomes and Practice Patterns
Study (PDOPPS) data, to (i) describe hypokalemia
prevalence in patients with PD from 7 countries; (ii)
identify modifiable risk factors associated with hypo-
kalemia in patients with PD; and (iii) test the following
hypotheses: (a) peritonitis and mortality will be higher
with persistent hypokalemia versus a brief2
hypokalemia exposure over a 4-month period; (b) low
potassium levels impact intestinal motility, which in-
creases the risk of peritonitis caused by enteric bacte-
ria; and (c) higher mortality seen in PD patients with
hypokalemia is related to poorer patient health and
nutritional status.
METHODS
Study Design and Data Source
PDOPPS is an international, prospective cohort study
of patients with PD $18 years of age designed to
identify modifiable practices associated with improve-
ments in PD technique and patient survival.15 Patients
were randomly selected from national samples of
randomly selected PD facilities treating $20 patients
with PD in Australia, Canada, Japan, New Zealand,
Thailand, the United Kingdom, and the United States,
as described previously.15 Study approval and patient
consent were obtained as required by national and local
ethics committee regulations.15 The current study in-
cludes patients enrolled in PDOPPS phase 1 (2014–
2017), excluding patients for reasons indicated in
Supplementary Figure S1.
The current study considers the 4 months before
enrollment as the “baseline” period. Patient de-
mographics, comorbidities, and medication pre-
scriptions were captured at study enrollment. Monthly
laboratory values were collected for the 4 months
before enrollment and during study follow-up. Peri-
tonitis episodes, permanent transfers to hemodialysis
(HD), and deaths were identified during study follow-
up. Data were abstracted from medical charts and
entered into a web-based data collection tool using
uniform data collection surveys and procedures.15 Data
from the US patients receiving care at large dialysis
organization (LDO) sites were imported from electronic
health records. The current study and results are re-
ported in accordance with the STROBE statement
checklist (Supplementary Table S4).
Statistical Analysis
We described serum potassium distributions by
country. Baseline patient characteristics and treatments
were described by mean potassium categories averaged
during the 4 months before enrollment (Kprior-4mo;
Figure 1).
Association of Serum Kprior-4mo With Peritonitis and
Mortality
Cox regression was used to estimate the effect of serum
potassium levels on primary outcomes of: 1) first all-cause
or organism category–specific peritonitis during follow-
up, and 2) all-cause mortality. For peritonitis outcomes
in 1), we used cause-specific Cox models to account forKidney International Reports (2021) -, -–-
Figure 1. Timing and definition of exposures and outcomes, by study objectives.
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Serum potassium exposures in all models were either
mean serum Kprior-4mo categories or number of months
having a serum potassium <4 mEq/l during the 4 months
before study entry. Since elevated peritonitis risk was
only seen at serum Kprior-4mo <3.5 mEq/l, a sensitivity
analysis was performed of the association of peritonitis
with number of months having a serum potassium <3.5
mEq/l. For peritonitis-related analyses, patients from fa-
cilities that did not routinely report peritonitis were
excluded, and those with missing organism information
were excluded from organism category–specific perito-
nitis analyses. As a secondary outcome, permanent
transfer to HD was also investigated in relationship to the
above primary exposures. All Cox models accounted for
facility clustering using robust sandwich-type covariance
estimators and were stratified by country, with the US
represented by 4 different strata (black vs. other race
[because higher rates of peritonitis have been seen in
black patients with PD18] and whether or not the facility
was part of an LDO). To assess the impact of covariate
adjustment on primary exposure hazard ratio estimates,
we applied increasing levels of covariate adjustment by
fitting 3 models for each outcome. Model 1 was only
stratified by country; model 2 was stratified by country
and adjusted for patient age, sex, end-stage kidney dis-
ease vintage, and 13 comorbidities (listed in Table 1); and
model 3 included model 2 adjustments and was also
adjusted for potassium balance factors indicated as model
3 adjustments in Figures 2 and 3.Kidney International Reports (2021) -, -–-In all outcome analyses, follow-up started at study
enrollment (after serum Kprior-4mo measurements and
after the baseline period). For mortality and permanent
transfer to HD, follow-up ended at death or trans-
plantation date, 7 days after permanent switch to HD,
loss to follow-up, or study end. Permanent transfer to
HD was defined as planned modality switch (clinician
reported) or temporary transfers from PD to HD that
did not return to PD within 12 weeks (84 days). Dying
within 7 days of transfer to HD was counted as a death
(outcome event)—not transfer. For peritonitis, patients
were followed until the first recorded peritonitis
episode and censored at the points noted above, in
addition to the date of the last returned peritonitis
questionnaire, whichever occurred first. Organism
classificatons for cause-specific peritonitis are listed in
Supplementary Table S1. Median follow-up time for
death and permanent transfer to HD was 1.2 years
(interquartile range [IQR] 0.6–1.9 years) compared with
0.8 years (IQR 0.3–1.3 years) for time to first peritonitis
episode.
Potassium Balance Factors Associated With Serum
Knext-4mo <4 mEq/l
We applied logistic generalized estimating equation
models to estimate the effects of potentially modifiable
baseline laboratory measurements and treatments (that
may potentially influence potassium balance) on the
odds of subsequent mean potassium <4 mEq/l
versus$4 mEq/l (reference), based on serum potassium3
Table 1. Patient demographics and comorbidities by serum Kprior-4mo
Serum Kprior-4mo, mEq/l
<3.5 3.5--3.9 4.0--4.4 4.5--4.9 ‡5.0
Patients, n 823 2019 2368 1555 656
Demographics and clinical characteristics
Age, yr, mean (SD) 58.7 (14.4) 60.6 (14.7) 59.1 (15.0) 57.5 (15.1) 55.3 (15.4)
Male, % 51 55 58 64 62
Black race in the US,a % 35 31 25 22 17
Years on PD,b median (IQR) 0.63 (0.07–1.80) 0.63 (0.26–1.52) 0.59 (0.27–1.49) 0.60 (0.22–1.52) 0.65 (0.16–1.54)
Years of ESKD, median (IQR) 0.97 (0.22–2.66) 1.09 (0.44–2.90) 1.09 (0.45–2.87) 1.16 (0.44–2.80) 1.19 (0.49–2.86)
Systolic blood pressure, mm Hg, mean (SD) 135 (26) 138 (24) 138 (23) 142 (24) 142 (24)
Diastolic blood pressure, mm Hg, mean (SD) 77.1 (14.9) 78.2 (14.2) 78.4 (13.3) 80.2 (13.9) 80.8 (14.0)
Caregiver(s) involved in PD exchanges, % 48 26 20 19 14
Comorbidities,c %
Coronary artery disease 15 20 22 20 21
Cancer (nonskin) 5 9 10 8 8
Other cardiovascular disease 10 13 12 13 9
Cerebrovascular disease 8 7 8 7 6
Congestive heart failure 15 14 13 13 10
Diabetes 52 48 46 44 46
Gastrointestinal bleeding 2 2 2 2 2
Hypertension 88 87 86 87 86
Lung disease 4 6 5 5 5
Neurologic disease 6 3 3 3 3
Psychiatric disorder 8 12 13 14 13
Peripheral vascular disease 9 13 13 13 9
Recurrent cellulitis/gangrene 2 2 2 1 2
ESKD, end-stage kidney disease; IQR, interquartile range; Kprior-4mo, average monthly serum potassium measured during the 4 months before study enrollment; PD, peritoneal dialysis;
SD, standard deviation; US, United States.
aThe overall US population is 26% black.
bExcludes patients from 1 large dialysis organization in the US.
cClasses of comorbidities as defined by Pisoni et al.32
CLINICAL RESEARCH SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PDmeasurements averaged over the 4 months after study
enrollment (Knext-4mo). Baseline predictors, based on
data at study enrollment, were grouped into 2 cate-
gories based on clinical judgement: 1) factors likely
associated with potassium intake and 2) factors likely
associated with increased/decreased potassium losses.
Analyses used an exchangeable working correlation to
account for clustering of patients within facilities.
Country-Specific Sensitivity Analyses
Given the high prevalence of low serum potassium in
Thailand, we excluded Thailand in sensitivity analyses
to test the robustness of our findings. Analyses also
were carried out restricted to the United States to
enable comparisons of outcomes with previously pub-
lished U.S. findings.1
Treatment of Missing Data
Missing values for all model covariates were
assumed to be missing at random and therefore
imputed using the sequential regression multiple
imputation method by IVEware and used in models
only.19 Results from 20 imputed datasets were
combined for the final analysis using a formula
from Little and Rubin.20 The proportion of patients
with PD with missing data was <15% for all4
imputed covariates, with the exception of 24-hour
urine volume (34% missing) and peritoneal Kt/V
urea (36% missing). Caregiver involvement, ico-
dextrin use, and PD solution glucose concentrations
were not available in U.S. LDOs. All analyses were
conducted with SAS software (version 9.4; SAS
Institute Inc., Cary, NC).RESULTS
Study Population and Distribution of Serum
Kprior-4mo Categories
A total of 7596 patients with PD from 216 facilities
enrolled in PDOPPS were included in the current study
(Supplementary Figure S1). The distribution of serum
Kprior-4mo varied considerably across PDOPPS countries
(Figure 4). Serum Kprior-4mo levels <4.0 mEq/l were
common in all countries, but especially in Thailand,
ranging from 24%–25% of patients in the United
Kingdom and Australia/New Zealand, 35% in Japan
and the United States, 39% in Canada, and 76% in
Thailand. Serum Kprior-4mo <3.5 mEq/l was relatively
uncommon (<12%) in all countries except Thailand
(46%).Kidney International Reports (2021) -, -–-
Figure 2. Associations (adjusted hazard ratio and 95% confidence interval [CI]), with progressive covariate adjustment, between (a) peritonitis
and average serum Kprior-4mo levels; (b) peritonitis and number of monthly serum Kprior-4mo measurements <4.0 mEq/l during the 4 months before
study enrollment; (c) all-cause mortality and average serum Kprior-4mo levels; and (d) all-cause mortality and number of monthly serum Kprior-4mo
measurements <4 mEq/l during the 4 months before study enrollment.
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Category
Table 1 shows summary statistics of patient char-
acteristics by mean serum Kprior-4mo categories. The
mean serum Kprior-4mo was based upon 4, 3, 2, and
1 month of data for 50%, 22%, 18%, and 11% of
patients, with 2% excluded because they had no
serum potassium measurements during this period.
Patients with lower Kprior-4mo were more likely to
be female, diabetic, have lower blood pressure,
have a history of congestive heart failure, be black
(in the United States only), and relied more on
caregivers. Other comorbidities were similar across
potassium levels.
Patients with lower serum Kprior-4mo levels tended
to have worse nutritional indicators (e.g., lower body
mass index, body weight, serum albumin, phos-
phorus, and urea), reduced muscle mass (e.g., lower
serum creatinine and creatinine production), higher
levels of inflammatory markers (e.g., higher C-reac-
tive protein and lower albumin), and lower residual
kidney function (Table 2). Dialysis and drug pre-
scription practices by baseline serum potassium
category are summarized in Table 3. Patients with
lower potassium (<3.5 mEq/l) were less likely to use
automated PD, icodextrin, or PD solutions containing
2.27% or 3.86% glucose but were prescribed a higher
daily total PD volume. They were less oftenKidney International Reports (2021) -, -–-prescribed beta blockers and angiotensin-converting
enzyme inhibitors or angiotensin II receptor
blockers, but were prescribed loop diuretics more
frequently compared with patients with higher po-
tassium levels.
Serum Kprior-4mo and Subsequent Clinical
Outcomes
Peritonitis
As shown in Figure 2a, there was an overall weak in-
verse association between mean serum Kprior-4mo levels
and first-episode peritonitis. For the fully adjusted
model (model 3), hazard ratios (HRs) for peritonitis
were 1.15 (95% confidence interval [CI], 0.96–1.37) and
0.93 (95% CI, 0.77–1.12), respectively, for mean serum
Kprior-4mo of <3.5 vs. $5.0 mEq/l, respectively,
compared with the reference group of 4.0–4.4 mEq/l (P
for overall trend ¼ 0.36). Progressive adjustment for
patient characteristics and treatments modestly atten-
uated the association from model 1. Similar results were
seen when including all countries except Thailand or
restricted only to the United States (Supplementary
Figures S2A and S3A).
Cause-specific results for enteric peritonitis
(Figure 3a) or Gram-negative peritonitis (Figure 3b)
showed few consistent associations with serum Kprior-
4mo levels. However, a tendency toward higher peri-
tonitis rates was seen at K <3.5 mEq/l in Gram-positive5
Figure 3. Associations (adjusted hazard ratio and 95% confidence interval [CI]), with progressive covariate adjustment, between (a) enteric
peritonitis; (b) Gram-negative peritonitis; (c) Gram-positive peritonitis; and (d) Gram-positive or culture-negative peritonitis and average serum
Kprior-4mo level measured during the 4 months before study enrollment.
CLINICAL RESEARCH SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PDperitonitis (model 3 adjusted HR for Kprior-4mo <3.5 vs.
Kprior-4mo 4.0–4.4 ¼ 1.14 [95% CI, 0.91–1.43]; Figure 3c)
and in Gram-positive or culture-negative peritonitis
(model 3 adjusted HR for Kprior-4mo <3.5 vs. Kprior-4mo
4.0–4.4 ¼ 1.15 [95% CI, 0.92–1.44]; Figure 3d).
We also examined the HRs of peritonitis in rela-
tionship to the number of months with serum Kprior-4mo
measurements <4.0mEq/l during the 4-month periodFigure 4. Proportion of patients in each potassium category across PDOPP
during the 4 months before study enrollment. A/NZ, Australia/New Zealan
6
before study enrollment (Figure 2b). No strong associ-
ation was found in this analysis; however, in a sensi-
tivity analysis looking at number of months with
serum Kprior-4mo measurements <3.5 mEq/l we found
that having a potassium measurement in each of the 4
months indicated higher rates of peritonitis with
persistent Kprior-4mo <3.5 mEq/l for 3 months (HR ¼
1.28 [95% CI, 0.94–1.73], model 3) and 4 months (HR ¼S countries, based on average monthly potassium values measured
d; UK, United Kingdom; US, United States.
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Table 2. Nutritional, metabolic, inflammatory, muscle mass, residual kidney function, and peritoneal clearance variables by serum Kprior-4mo
Serum Kprior-4mo, mEq/l
<3.5 3.5--3.9 4.0--4.4 4.5--4.9 ‡5.0
Patients, n 823 2019 2368 1555 656
Nutritional, mean (SD)
Body mass index, kg/m2 24.6 (5.7) 27.3 (6.2) 27.7 (6.3) 27.5 (6.0) 28.2 (6.2)
Serum bicarbonate, mEq/l 27.1 (3.5) 26.1 (3.3) 25.3 (3.3) 24.5 (3.4) 23.7 (3.5)
Serum phosphorus, mg/dl 4.27 (1.44) 4.78 (1.36) 5.13 (1.40) 5.44 (1.47) 5.97 (1.68)
Serum magnesium, mg/dl 1.96 (0.51) 2.06 (0.42) 2.15 (0.47) 2.23 (0.49) 2.27 (0.49)
Serum albumin, g/dl 3.19 (0.70) 3.39 (0.56) 3.43 (0.57) 3.48 (0.54) 3.51 (0.51)
Body weight, kg 65.5 (19.1) 76.1 (21.3) 78.4 (21.7) 78.5 (20.9) 80.4 (21.9)
Serum urea, mg/dl 86 (401) 105 (326) 128 (515) 154 (635) 267 (1032)
Metabolic, mean (SD)
Glucose, mg/dl 144 (76) 144 (78) 141 (73) 138 (75) 134 (68)
Total cholesterol, mg/dl 178 (51) 172 (48) 176 (51) 175 (47) 170 (43)
Triglycerides, mg/dl 175 (121) 175 (106) 181 (132) 163 (103) 160 (94)
HbA1C for diabetic patients, % 7.20 (1.63) 7.44 (3.32) 7.06 (1.54) 7.09 (3.39) 6.99 (1.53)
Uric acid, mg/dl 6.38 (1.78) 6.23 (1.66) 6.14 (1.48) 6.17 (1.45) 6.07 (1.44)
Inflammatory, median (IQR)
C-reactive protein,a mg/dl 0.40 (0.11–1.20) 0.33 (0.14–0.95) 0.30 (0.11–0.83) 0.25 (0.10–0.60) 0.30 (0.10–0.80)
Muscle mass, mean (SD)
Creatinine generation rate,b g/d per 1.73 m2 13.1 (19.9) 16.4 (20.9) 19.3 (20.7) 21.8 (23.9) 20.9 (22.1)
Serum creatinine, mg/dl 8.08 (3.56) 8.11 (3.70) 8.50 (3.92) 9.15 (4.12) 9.67 (4.16)
RKF, peritoneal clearance, and membrane function
Peritoneal creatinine clearance, liter/week, mean (SD) 49.6 (26.8) 46.1 (28.0) 45.2 (33.3) 41.6 (30.1) 42.6 (28.4)
rGFR, ml/min per 1.73 m2, mean (SD) 2.29 (3.41) 2.76 (3.73) 3.15 (3.75) 3.36 (4.00) 2.72 (3.49)
24-h urine volume, liters, mean (SD) 0.59 (0.65) 0.73 (0.69) 0.91 (0.75) 1.00 (0.82) 0.99 (0.83)
Total Kt/V urea, mean (SD) 2.21 (0.78) 2.31 (0.72) 2.33 (0.69) 2.24 (0.70) 2.20 (0.72)
Peritoneal Kt/V urea, mean (SD) 1.59 (0.57) 1.52 (0.55) 1.41 (0.50) 1.35 (0.52) 1.37 (0.57)
PSTR, mean (SD) 0.70 (0.13) 0.67 (0.14) 0.68 (0.14) 0.68 (0.14) 0.68 (0.14)
Net 24-h peritoneal ultrafiltration, ml, median (IQR) 700 (200–1191) 746 (312–1394) 719 (250–1229) 700 (201–1286) 748 (286–1510)
24-h urine volume plus net 24-hr ultrafiltration, liters, median (IQR) 1.25 (0.80–1.78) 1.50 (0.95–2.18) 1.65 (1.10–2.27) 1.75 (1.23–2.36) 1.90 (1.30–2.58)
HbA1C, glycosylated hemoglobin; IQR, interquartile ratio; Kprior-4mo, average monthly serum potassium measured during the 4 months before study enrollment; PSTR, peritoneal solute
transport rate (dialysate/plasma creatinine ratio at 4 hrs); rGFR, residual glomerular filtration rate (mean of the urinary creatinine and the urea clearance); RKF, residual kidney function;
SD, standard deviation.
aRarely measured in Canada, Thailand, and the United States.
bCalculation of the total creatinine mass removed.
SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PD CLINICAL RESEARCH1.83 [95% CI, 1.26–2.68], model 3) versus those who
never had Kprior-4mo <3.5 mEq/l (Supplementary
Figure S4). A similar pattern was seen when
including all countries except Thailand or restricted
only to the United States (Supplementary Figures S2A
and S3B).
Mortality and Permanent Transfer to HD
Mortality was inversely associated with mean serum
Kprior-4mo levels when adjusting only for country
(Figure 2c; model 1, P for trend < 0.01), but this as-
sociation was markedly attenuated when adjusting for
other covariates, especially in model 3 (P for trend ¼
0.5). Sensitivity analyses excluding Thailand
(Supplementary Figure S2B) or restricting to only the
United States (Supplementary Figure S3B) yielded re-
sults similar to those in Figure 2c for all countries.
Results also were similar in analyses exploring the
impact of defining potassium <4.0 mEq/l based upon
the single most recent measurement during the 4
months before study enrollment (SupplementaryKidney International Reports (2021) -, -–-Table S2). In contrast, when mortality was examined
in relationship to number of monthly serum Kprior-4mo
measurements <4.0 mEq/l (Figure 2d), patients with a
potassium level <4 mEq/l in 2, 3, or 4 out of 4 months
generally had greater mortality (HRs 1.19–1.41, model
3) compared with patients with no potassium
measurements <4 mEq/l over 4 months.
Since hypokalemia was associated with higher risks
of peritonitis, and because peritonitis is one of the major
causes requiring patients’ permanent transfer to HD, we
investigated whether permanent transfer from PD to HD
was greater at low serum potassium levels. No consistent
association was seen between mean serum Kprior-4mo and
permanent transfer to HD, although patients with Kprior-
4mo levels 4.5–4.9 mEq/l had a lower transfer rate than
did patients in other groups (Supplementary
Figure S5A). Furthermore, weak associations were seen
between the number of monthly serum Kprior-4mo
measurements<4.0mEq/l over 4months and permanent
transfer to HD (Supplementary Figure S5B). Sensitivity
analyses excluding Thailand or restricted to the United7
Table 3. PD prescription and medication prescription by serum
Kprior-4mo
Serum Kprior4mo, mEq/L
<3.5 3.5--3.9 4.0--4.4 4.5--4.9 ‡5.0
Patients, n 823 2019 2368 1555 656
PD prescription, %
APD 36 65 71 71 68
Wet day (APD) 51 47 43 41 40
Icodextrin 19 34 38 38 40
PD solution glucose concentrations
Use of 2.27% but not 3.86% 32 46 50 47 46
Use of any 3.86% 11 17 14 14 15
Without any 2.27% or 3.86%
use
58 37 36 39 40

























RASi (ACEi or ARB) 38 39 44 52 56
Insulin (proportion of diabetic
patients only)
50 54 53 55 52
Beta-blocker 38 50 52 54 56
Any diuretic 55 52 51 51 47
Potassium sparing diuretic
(aldosterone antagonist)
4 4 3 3 2
Loop diuretic 53 49 49 49 45
Thiazide diuretic 4 6 6 6 6
ACEi, angiotensin-converting enzyme inhibitor; APD, automated peritoneal dialysis;
ARB, angiotensin II receptor blockers; BMI, body mass index; BSA, body surface area;
Kprior-4mo, average monthly serum potassium measured during the 4 months before study
enrollment; RASi, renin-angiotensin system inhibition; SD, standard deviation.
CLINICAL RESEARCH SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PDStates had similar results (Supplementary Figures S2C
and S3C).
Predictors of Serum Knext-4mo <4 mEq/l
Logistic regression was used to evaluate baseline fac-
tors associated with the odds of having a mean serum
Knext-4mo <4 vs. $4 mEq/l in the 4-month period after
study entry (Table 4). The mean serum Knext-4mo was
based upon 1, 2, 3, or 4 months of data for 9%, 16%,
21%, and 54% of patients. Adjusted odds of serum
Knext-4mo <4 mEq/l were greater with higher serum
bicarbonate levels (reflecting reduced protein intake),
higher dialysis dose, lower serum phosphorus, creati-
nine, albumin, and urine volume levels, and with
prescription of icodextrin or loop diuretics. Patients
who were prescribed an angiotensin-converting
enzyme inhibitor or angiotensin II receptor blocker
were less likely to have serum Knext-4mo <4 mEq/l.
Results were similar in sensitivity analyses with Knext-
4mo <3.5 mEq/l as the outcome (Supplementary
Table S3).
DISCUSSION
We observed large variations in the prevalence of
hypokalaemia among the PDOPPS countries in this8
large, multinational cohort study, with the highest
prevalence among patients from Thailand (76%). We
have no reason to suspect serum potassium measure-
ment to meaningfully differ across any of the countries.
However, cultural dietary differences could contribute
to the observed national differences in serum potassium
levels. Moreover, a recent meta-analysis found signifi-
cant differences in the prevalence of protein-energy
wasting in chronic kidney disease with a high preva-
lence in southeast Asia. Hypokalemia may serve as a
surrogate for protein-energy wasting, which may
explain our findings of a higher prevalence of hypo-
kalemia among patients with PD in Thailand.21 Lower
serum potassium levels in black Americans is consis-
tent with previous observations in both healthy and
chronic kidney disease populations.22,23
Serum Kprior-4mo <3.5 mEq/l—particularly if per-
sisting over several months—was associated with
higher peritonitis risk caused by any organism, as in
the BRAZPD,2 and tended to be associated with Gram-
positive organisms. Previous studies raised concerns
that hypokalemia might increase the risk for infections
originating from the gastrointestinal tract, possibly by
reducing gut motility.8 However, we found no
discernible increase in enteric or Gram-negative in-
fections, failing to support the hypothesis that higher
peritonitis rates with hypokalemia occur via infections
originating from the gastrointestinal tract. Adjusting
for many potential confounders had a relatively modest
effect on the association between peritonitis and
persistent hypokalemia, such that patients with serum
potassium levels <3.5 mEq/l for 3 or 4 months over 4
months displayed 28% and 83% higher adjusted
peritonitis hazards, respectively.
In contrast to previous large cohort studies,1–3 the
effect of mean serum Kprior-4mo <4.0 mEq/l on increased
mortality was markedly attenuated in our PDOPPS
cohort after adjustment for suspected confounders. We
uniquely adjusted for additional potential confounders
including dialysis prescriptions, residual kidney
function, frailty indicators, and medications known to
alter potassium excretion. These additional adjustments
markedly attenuated the effect of mean serum Kprior-
4mo <4.0 mEq/l on mortality, suggesting that the as-
sociation observed before adjustment, and seen in
previous studies, may be explained by the additional
factors (e.g., protein-energy malnutrition and other
confounding factors). It is noteworthy that the relative
proportions of “incident” patients (short time on PD)
versus “prevalent” patients (longer time on PD) in the
large previous cohort studies varied, ranging from
excluding prevalent patients in the BRAZPD3 to 75% of
patients on PD $1 year (IQR, 12–54 months) in the
DaVita Study.1 In contrast, our PDOPPS cohortKidney International Reports (2021) -, -–-
Table 4. Association (adjusted prevalence OR and 95% CI) between
potentially modifiable baseline factors and average serum Knext-
4mo <4.0 mEq/l
Potentially modifiable factors
Adjusted model Aa Adjusted model Bb
OR (95% CI) OR (95% CI)
Laboratory values
Serum phosphorous, per 1 mg/dl 0.84 (0.81–0.88) 0.88 (0.84–0.93)
Serum bicarbonate, per 1 mEq/l 1.09 (1.07–1.11) 1.04 (1.02–1.06)
Serum creatinine, per 1 mg/dl 0.97 (0.95–0.98) 0.95 (0.93–0.97)
Serum albumin, per 1 g/dl 0.75 (0.68–0.84) 0.85 (0.77–0.94)
PD treatment variables
PD modality, APD vs. CAPD 0.90 (0.79–1.03) 0.90 (0.79–1.03)
Icodextrin use 1.36 (1.16–1.59) 1.21 (1.01–1.44)
PD solution glucose concentrations
Without any 2.27% or 3.86% use 1 (reference) 1 (reference)
Use of 2.27% but not 3.86% 1.37 (1.09–1.71) 1.22 (0.98–1.53)
Use of any 3.86% 1.31 (0.98–1.77) 1.14 (0.83–1.56)
Urine volume, per 1 liter/24 h 0.68 (0.62–0.75) 0.68 (0.60–0.78)
Loop diuretic 1.09 (0.96–1.24) 1.19 (1.05–1.36)
RASi (ACEi or ARB) 0.74 (0.65–0.84) 0.74 (0.65–0.85)
Peritoneal Kt/V urea, per 0.1 1.04 (1.03–1.06) 1.02 (1.00–1.04)
Caregiver involvement in PD exchanges,
involved vs. not involved
1.17 (0.99–1.38) 1.04 (0.86–1.25)
ACEi, angiotensin-converting enzyme inhibitors; APD, automated peritoneal dialysis;
ARB, angiotensin II receptor blocker; CAPD, continuous ambulatory peritoneal dialysis;
CI, confidence interval; Knext-4mo, average monthly serum potassium measured during
the 4 months after study enrollment; OR, odds ratio; PD, peritoneal dialysis; RASi, renin-
angiotensin system inhibition.
aEstimates in each row from separate models adjusted for patient age, sex, time since
end-stage kidney disease, country, and 13 comorbidities.
bAll estimates from a single model adjusted for all factors in the table as well as ad-
justments in model A.
SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PD CLINICAL RESEARCHincluded a mixture of incident and longer-term prev-
alent patients with PD, with a median of 7 months
(IQR, 3–18 months) on PD therapy at enrollment.
Finally, our results were robust to analyses that
excluded patients from Thailand (where hypokalemia
prevalence is high) or restricted to patients in the
United States. These 2 countries had the highest and
lowest peritonitis rates (0.40 and 0.26 episodes per
patient-year in Thailand and the United States,
respectively, in 2014–2017) in a recent study of
PDOPPS countries by Perl et al.18
Previous studies variably defined hypokalemia,
typically using monthly time-averaged values over an
observational period.1,2 In the present study, patients
having serum potassium levels <4.0 mEq/l for 2, 3, or 4
months over 4 months displayed 28%, 19%, and 41%
higher adjusted mortality hazards, respectively, versus
0 months <4.0 mEq/l. Having 2–4 months with serum
potassium <4 mEq/l (vs. 0 months at this level) was a
substantially stronger predictor of mortality (30%–
40% higher) in fully adjusted models than having a
mean serum potassium <4 mEq/l (vs. 4.0–4.49 mEq/l)
over the 4-month exposure period.
We also analyzed additional factors at PDOPPS
study enrollment for their association with mean serum
potassium over the subsequent 4 months (Knext-Kidney International Reports (2021) -, -–-4mo <4.0 mEq/l). Lower serum albumin was associated
with higher odds of Knext-4mo <4.0 mEq/l, with low
serum albumin known to be associated with increased
peritoneal protein losses,24 inflammation,25 frailty,26
and reduced dietary protein intake in patients with
PD. Greater residual kidney function may improve
dietary intake and preservation of muscle mass,24 as
shown in longitudinal studies of body composition.27
Furthermore, in a study by Wang et al.,28 a signifi-
cant and independent effect of residual kidney func-
tion on actual daily protein intake, daily caloric intake,
and other nutrient intake in patients on continuous
ambulatory PD was observed.
Moreover, residual kidney function is important for
potassium excretion as kidney disease progresses and
similarly can benefit dialysis patients. This may explain
the inverse relationship between daily urine volume and
odds of Knext-4mo <4.0 mEq/l, and with this relationship
being similar whether adjusting or not for serum albumin
and creatinine as nutritional and muscle mass surrogate
measures. Loop diuretics were positively associated and
renin-angiotensin system blockers inversely associated
with Knext-4mo <4.0 mEq/l. However, these effects are
dependent on residual kidney function. Notably, a recent
analysis from the BRAZPD found no association between
stopping or starting renin-angiotensin system blockers
and serum potassium levels.29
Our study has several limitations. As with any
observational analysis, we cannot control for unmea-
sured confounders. We did not use some established
measures of nutritional status or body composition,
e.g., the subjective global assessment or bioimpedance
analysis, both powerful predictors of survival in pa-
tients with PD.30,31 However, these are not widely used
in routine practice and were not part of the PDOPPS
dataset. Strengths of our study include the use of many
relevant factors for model adjustments, large sample
size, and including countries with quite different so-
cioeconomic circumstances and patient mix. The pro-
spective collection of numerous patient characteristics
and clinical practice patterns developed via work-
groups of international experts has allowed PDOPPS to
conduct the most comprehensive analysis of the asso-
ciations of serum potassium to date.
How should these observations influence clinical
practice? These observations suggest that clinicians
should pay more attention to hypokalemia and recog-
nize that while it is a possible risk factor for death and
possibly peritonitis in PD, preventive efforts should
focus on factors associated with hypokalemia (e.g.,
poor nutrition and wasting). Our findings of substan-
tially stronger risks of death and peritonitis with
persistent hypokalemia should stimulate investigation
of interventions that minimize the duration of9
CLINICAL RESEARCH SJ Davies et al.: Hypokalemia and Mortality/Peritonitis in Patients With PDhypokalemia given our identification of potentially
modifiable factors. For example, increasing PD pre-
scription or using high-dose diuretics in an attempt to
maintain urine output may be appropriate but might
exacerbate hypokalemia risk that could be mitigated
with potassium supplements. Until appropriately
designed trials have established a causative role for low
serum potassium in reduced survival and greater
peritonitis risk, it seems prudent that increasing PD
prescription should be done with careful monitoring
for the development of persistent hypokalemia. Dietary
counselling to encourage the intake of vegetables and
fruits, the avoidance of inappropriate dietary potas-
sium, restriction, and nutrition support to maintain
good nutritional status (from the start of PD) combined
with potential interventions to increase serum potas-
sium, if needed, seem appropriate.DISCLOSURE
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